Literature DB >> 16546089

CTLA4Ig: bridging the basic immunology with clinical application.

Jeffrey A Bluestone1, E William St Clair, Laurence A Turka.   

Abstract

After a very long and windy road, in December of 2005 the FDA approved CTLA4Ig for the treatment of rheumatoid arthritis. Orencia is the first-in-class antagonist of CD28 costimulation. In this perspective, we discuss the science that led to CTLA4Ig development and the clinical challenges in bringing the drug from the bench to the bedside.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16546089     DOI： 10.1016/j.immuni.2006.03.001

Source DB:  PubMed          Journal:  Immunity        ISSN： 1074-7613            Impact factor:   31.745


  92 in total

Review 1.  Generation, persistence and plasticity of CD4 T-cell memories.

Authors:  Jason R Lees; Donna L Farber
Journal:  Immunology       Date:  2010-05-10       Impact factor: 7.397

Review 2.  Modification of accessory molecule signaling.

Authors:  Mary K Crow
Journal:  Springer Semin Immunopathol       Date:  2006-05-16

3.  PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection.

Authors:  Katsunori Tanaka; Monica J Albin; Xueli Yuan; Kazuhiro Yamaura; Antje Habicht; Takaya Murayama; Martin Grimm; Ana Maria Waaga; Takuya Ueno; Robert F Padera; Hideo Yagita; Miyuki Azuma; Tahiro Shin; Bruce R Blazar; David M Rothstein; Mohamed H Sayegh; Nader Najafian
Journal:  J Immunol       Date:  2007-10-15       Impact factor: 5.422

Review 4.  The potential for immunogenicity of autologous induced pluripotent stem cell-derived therapies.

Authors:  Zachary S Scheiner; Sohel Talib; Ellen G Feigal
Journal:  J Biol Chem       Date:  2013-12-20       Impact factor: 5.157

5.  An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's).

Authors:  Carol A Langford; Paul A Monach; Ulrich Specks; Philip Seo; David Cuthbertson; Carol A McAlear; Steven R Ytterberg; Gary S Hoffman; Jeffrey P Krischer; Peter A Merkel
Journal:  Ann Rheum Dis       Date:  2013-12-09       Impact factor: 19.103

6.  Scavenging nucleic acid debris to combat autoimmunity and infectious disease.

Authors:  Eda K Holl; Kara L Shumansky; Luke B Borst; Angela D Burnette; Christopher J Sample; Elizabeth A Ramsburg; Bruce A Sullenger
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-15       Impact factor: 11.205

Review 7.  The promise and challenges of immune agonist antibody development in cancer.

Authors:  Patrick A Mayes; Kenneth W Hance; Axel Hoos
Journal:  Nat Rev Drug Discov       Date:  2018-06-15       Impact factor: 84.694

Review 8.  CD28 Costimulation: From Mechanism to Therapy.

Authors:  Jonathan H Esensten; Ynes A Helou; Gaurav Chopra; Arthur Weiss; Jeffrey A Bluestone
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

Review 9.  Clinical immunologic interventions for the treatment of type 1 diabetes.

Authors:  Lucienne Chatenoud; Katharina Warncke; Anette-G Ziegler
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

10.  B7 blockade alters the balance between regulatory T cells and tumor-reactive T cells for immunotherapy of cancer.

Authors:  Penghui Zhou; Xincheng Zheng; Huiming Zhang; Yang Liu; Pan Zheng
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.